IACS-70654

IACS-70654 is a selective small-molecule inhibitor of the CREB-binding protein (CBP) and E1A-associated protein p300 (EP300) bromodomains (BRD). Developed by the Institute for Applied Cancer Science (IACS) at the University of Texas MD Anderson Cancer Center, IACS-70654 targets the epigenetic reader function of CBP/P300. In preclinical models of triple-negative breast cancer (TNBC), particularly those enriched with tumor-associated neutrophils (TANs), IACS-70654 has been shown to reduce immunosuppressive TAN accumulation, inhibit abnormal myelopoiesis in the bone marrow, and stimulate antitumor immunity by inducing interferon (IFN) responses and major histocompatibility complex class I (MHCI) expression. It also enhances the efficacy of standard-of-care therapies, such as docetaxel and immune checkpoint blockade.